Organigram Global Inc.

TSX:OGI Stock Report

Market Cap: CA$192.9m

Organigram Global Future Growth

Future criteria checks 4/6

Organigram Global is forecast to grow earnings and revenue by 78.6% and 13.8% per annum respectively while EPS is expected to grow by 48.5% per annum.

Key information

78.6%

Earnings growth rate

48.47%

EPS growth rate

Pharmaceuticals earnings growth12.6%
Revenue growth rate13.8%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Jul 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 26

OGI: Sanity Group Acquisition Will Reshape Revenue Profile And Future Earnings Potential

Analysts have reset their fair value estimate for Organigram Global from CA$2.85 to CA$1.65. They cited updated assumptions on discount rate, revenue growth, profit margin and future P/E as the key drivers behind the new price target.
Analysis Article • Feb 19

Shareholders Will Be Pleased With The Quality of Organigram Global's (TSE:OGI) Earnings

Even though Organigram Global Inc. ( TSE:OGI ) posted strong earnings, investors appeared to be underwhelmed. We have...
Analysis Article • Feb 12

Organigram Global Inc. (TSE:OGI) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing

Organigram Global Inc. ( TSE:OGI ) shares have had a horrible month, losing 26% after a relatively good period...
Analysis Article • Dec 19

Organigram Global Inc. (TSE:OGI) Soars 33% But It's A Story Of Risk Vs Reward

Organigram Global Inc. ( TSE:OGI ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Sep 30

Are Investors Undervaluing Organigram Global Inc. (TSE:OGI) By 50%?

Key Insights Organigram Global's estimated fair value is CA$5.45 based on 2 Stage Free Cash Flow to Equity Organigram...
Analysis Article • Aug 01

Why We're Not Concerned About Organigram Global Inc.'s (TSE:OGI) Share Price

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Analysis Article • Jun 09

Organigram Holdings Inc.'s (TSE:OGI) P/S Is On The Mark

There wouldn't be many who think Organigram Holdings Inc.'s ( TSE:OGI ) price-to-sales (or "P/S") ratio of 1.1x is...

Earnings and Revenue Growth Forecasts

TSX:OGI - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202847011N/AN/A2
9/30/2027436429385
9/30/202633618-18-95
3/31/2026274-25-21-10N/A
12/31/202528018-37-19N/A
9/30/2025259-25-25-8N/A
6/30/20252248-173N/A
3/31/202519417-27-16N/A
12/31/2024166-53-13-8N/A
9/30/2024160-45-14N/A
9/30/2023149-229-64-36N/A
5/31/2023161-222-80-41N/A
2/28/2023166-11-89-42N/A
11/30/2022159-8-74-23N/A
8/31/2022146-14-85-36N/A
5/31/2022125-34-63-24N/A
2/28/2022107-35-53-29N/A
11/30/202190-98-56-38N/A
8/31/202179-131-41-29N/A
5/31/202175-143-44-29N/A
2/28/202172-229-46-17N/A
11/30/202081-170-80-18N/A
8/31/202087-136-124-45N/A
5/31/202083-120-156-53N/A
2/29/202089-40N/A-50N/A
11/30/201993-40N/A-47N/A
8/31/201980-10N/A-35N/A
5/31/20196731N/A-26N/A
2/28/20194645N/A-29N/A
11/30/20182253N/A-24N/A
8/31/20181222N/A-13N/A
5/31/2018112N/A-10N/A
2/28/201810-4N/A-13N/A
11/30/20176-11N/A-14N/A
8/31/20175-11N/A-9N/A
5/31/20175-8N/A-5N/A
2/28/20175-6N/A-3N/A
11/30/201670N/A0N/A
8/31/201661N/A-2N/A
5/31/201650N/A-2N/A
2/29/201630N/A-3N/A
11/30/20152-1N/A-2N/A
8/31/20151-1N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OGI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3%).

Earnings vs Market: OGI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OGI is expected to become profitable in the next 3 years.

Revenue vs Market: OGI's revenue (13.8% per year) is forecast to grow faster than the Canadian market (4.3% per year).

High Growth Revenue: OGI's revenue (13.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OGI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/05 03:00
End of Day Share Price 2026/08/05 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Organigram Global Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)